Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.

ABSTRACT: Special populations, including children and pregnant women, have been neglected in tuberculosis drug development. Patients in developing countries are inadequately represented in pharmacology research, and postmarketing pharmacovigilance activities tend to be rudimentary in these settings. There is an ethical imperative to generate evidence at an early stage to support optimal treatment in these populations and in populations with common comorbid conditions, such as diabetes and human immunodeficiency virus (HIV) infection. This article highlights the research needed to support equitable access to new antituberculosis regimens. Efficient and opportunistic pharmacokinetic study designs, typically using sparse sampling and population analysis methods, can facilitate optimal dose selection fo

SUBMITTER: McIlleron H 

PROVIDER: S-EPMC4551115 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature